Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2021 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are doing and scaling. Let me analyze the transcript carefully. Key elements to check: 1. Does management speak about counterparties' business as part of its own? 2. Is the company already inside that growth (supplying, serving, embedded)? 3. Is the counterparties' trajectory early and large relative to the company? Let me review the transcript: Tony Thene's comments: - "We saw demand conditions improve sequentially across our major end-use markets, including Aerospace and Defense and Medical." - "Customer engagement around Athens remains high as we continue to broaden our capabilities and customer base." - "We are already producing materials to support new [eviation] [ph] motors that are in the process of FAA certification. We are also producing products for sensors and resistors that are now in newer more advanced electric vehicle electronic systems." - "A growing number of our customers are pointing to further demand acceleration in early calendar year 2022." - "Looking ahead, our customers expect order rates and backlog to show further improvement in the current quarter as the overall market continues to ramp in support of the ongoing recovery in elective surgeries." - "It is predicted that orthopedic procedures will reach 85% to 90% of pre-pandemic levels in the coming quarter. Cardiovascular procedures will reach 80% to 85% of pre-pandemic levels." The question is whether management's forward account consists of reporting on the growth/expansion/ramp of specific customers, partners, etc., that the company already supplies, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Looking at the transcript, management discusses: - Demand conditions improving across end-use markets - Customer expectations for order rates and backlog improvement - Predictions about orthopedic and cardiovascular procedures reaching pre-pandemic levels - Producing materials for motors in FAA certification process - Producing products for sensors and resistors in electric vehicles However, the discussion is largely at the level of end-use markets (aerospace, medical, transportation, energy, industrial) rather than specific named counterparties with their own ramps, launches, or build-outs.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.